KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $49.9 million.

  • Resmed's Depreciation & Amortization (CF) rose 742.05% to $49.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $204.9 million, marking a year-over-year increase of 1489.73%. This contributed to the annual value of $198.5 million for FY2025, which is 1221.41% up from last year.
  • As of Q4 2025, Resmed's Depreciation & Amortization (CF) stood at $49.9 million, which was up 742.05% from $47.7 million recorded in Q3 2025.
  • Resmed's 5-year Depreciation & Amortization (CF) high stood at $63.6 million for Q2 2025, and its period low was $36.3 million during Q3 2022.
  • In the last 5 years, Resmed's Depreciation & Amortization (CF) had a median value of $43.7 million in 2024 and averaged $43.7 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 740.89% in 2022, then soared by 4567.52% in 2025.
  • Resmed's Depreciation & Amortization (CF) (Quarter) stood at $40.8 million in 2021, then dropped by 7.41% to $37.8 million in 2022, then increased by 18.58% to $44.8 million in 2023, then grew by 3.7% to $46.4 million in 2024, then rose by 7.42% to $49.9 million in 2025.
  • Its Depreciation & Amortization (CF) was $49.9 million in Q4 2025, compared to $47.7 million in Q3 2025 and $63.6 million in Q2 2025.